ArticleWorld psychiatry : official journal of the World Psychiatric Association (WPA)2015
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.
Article in World psychiatry : official journal of the World Psychiatric Association (WPA), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 369 papers, 19 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
369 citing papers in PubMed, 19 syntheses or guidelines pooled it, 796 citations in OpenAlex.
- Precipitants and clinical features of serotonin syndrome: a systematic review with patient-level analysis of published case reports and series.European journal of clinical pharmacology · 2026Pooled it
- Psychosocial and Demographic Factors Associated with Physical Multimorbidity in Severe Mental Illness: A Systematic Review.Schizophrenia bulletin · 2026Pooled it
- Effectiveness of specialist-delivered interventions in severe mental illness: A systematic review and meta-analysis.The Australian and New Zealand journal of psychiatry · 2026Pooled it
- The eye-mind connection: a systematic review of retinal biomarkers and ocular signatures in major psychiatric disorders.European journal of medical research · 2025Pooled it
- Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence.European child & adolescent psychiatry · 2025Pooled it
- Effects of physical exercise on metabolic syndrome in psychotic disorders: A systematic review with meta-analysis of randomized controlled trials.European psychiatry : the journal of the Association of European Psychiatrists · 2025Pooled it
- Lurasidone versus typical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2025Pooled it
- EPA guidance on lifestyle interventions for adults with severe mental illness: A meta-review of the evidence.European psychiatry : the journal of the Association of European Psychiatrists · 2024Pooled it
- Efficacy and safety of lumateperone for bipolar depression and schizophrenia: a systematic review and meta-analysis.The international journal of neuropsychopharmacology · 2024Pooled it
- Risk of renal impairment in atypical antipsychotics: a systematic review and meta-analysis.European journal of clinical pharmacology · 2024Pooled it
- The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients.BMC cancer · 2024Pooled it
- Effectiveness of Psychobiotics in the Treatment of Psychiatric and Cognitive Disorders: A Systematic Review of Randomized Clinical Trials.Nutrients · 2024Pooled it
- An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs.Neuroscience and biobehavioral reviews · 2023Pooled it
- Association between impaired glucose metabolism and long-term prognosis at the time of diagnosis of depression: Impaired glucose metabolism as a promising biomarker proposed through a machine-learning approach.European psychiatry : the journal of the Association of European Psychiatrists · 2023Pooled it
- Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis.Frontiers in psychiatry · 2023Pooled it
- Effectiveness of nutrition and dietary interventions for people with serious mental illness: systematic review and meta-analysis.The Medical journal of Australia · 2022Pooled it
- Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Pooled it
- Bipolar disorder and the risk for stroke incidence and mortality: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Pooled it
- The Association Between Personality Traits and Dietary Choices: A Systematic Review.Advances in nutrition (Bethesda, Md.) · 2021Pooled it
- Trial
309 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with severe mental illness have a considerably shorter lifespan than the general population. This excess mortality is mainly due to physical illness. Next to mental illness-related factors, unhealthy lifestyle, and disparities in health care access and utilization, psychotropic medications can contribute to the risk of physical morbidity and mortality. We systematically reviewed the effects of antipsychotics, antidepressants and mood stabilizers on physical health outcomes in people with schizophrenia, depression and bipolar disorder. Updating and expanding our prior systematic review published in this journal, we searched MEDLINE (November 2009 - November 2014), combining the MeSH terms of major physical disease categories (and/or relevant diseases within these categories) with schizophrenia, major depressive disorder and bipolar disorder, and the three major psychotropic classes which received regulatory approval for these disorders, i.e., antipsychotics, antidepressants and mood stabilizers. We gave precedence to results from (systematic) reviews and meta-analyses wherever possible. Antipsychotics, and to a more restricted degree antidepressants and mood stabilizers, are associated with an increased risk for several physical diseases, including obesity, dyslipidemia, diabetes mellitus, thyroid disorders, hyponatremia; cardiovascular, respiratory tract, gastrointestinal, haematological, musculoskeletal and renal diseases, as well as movement and seizure disorders. Higher dosages, polypharmacy, and treatment of vulnerable (e.g., old or young) individuals are associated with greater absolute (elderly) and relative (youth) risk for most of these physical diseases. To what degree medication-specific and patient-specific risk factors interact, and how adverse outcomes can be minimized, allowing patients to derive maximum benefits from these medications, requires adequate clinical attention and further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.